Free Trial

Terns Pharmaceuticals (TERN) Competitors

Terns Pharmaceuticals logo
$6.05 +0.29 (+5.03%)
(As of 12/19/2024 05:31 PM ET)

TERN vs. LBPH, NAMS, IDYA, RXRX, CNTA, APGE, IBRX, WVE, MIRM, and AKRO

Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Longboard Pharmaceuticals (LBPH), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Terns Pharmaceuticals vs.

Terns Pharmaceuticals (NASDAQ:TERN) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

Terns Pharmaceuticals currently has a consensus target price of $18.30, suggesting a potential upside of 202.48%. Longboard Pharmaceuticals has a consensus target price of $59.56, suggesting a potential downside of 0.71%. Given Terns Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Longboard Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Longboard Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44

Longboard Pharmaceuticals has lower revenue, but higher earnings than Terns Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns Pharmaceuticals$1M513.88-$90.21M-$1.18-5.13
Longboard PharmaceuticalsN/AN/A-$54.42M-$2.23-26.90

Longboard Pharmaceuticals received 21 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 75.00% of users gave Longboard Pharmaceuticals an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Terns PharmaceuticalsOutperform Votes
42
60.87%
Underperform Votes
27
39.13%
Longboard PharmaceuticalsOutperform Votes
63
75.00%
Underperform Votes
21
25.00%

Terns Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Longboard Pharmaceuticals had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 3 mentions for Longboard Pharmaceuticals and 2 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.97 beat Longboard Pharmaceuticals' score of 0.00 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Longboard Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Terns Pharmaceuticals' return on equity of -32.76% beat Longboard Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -32.76% -31.33%
Longboard Pharmaceuticals N/A -33.03%-30.90%

Summary

Terns Pharmaceuticals beats Longboard Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TERN vs. The Competition

MetricTerns PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$513.88M$6.65B$5.00B$8.98B
Dividend YieldN/A3.08%4.87%4.13%
P/E Ratio-5.1310.44135.2517.00
Price / Sales513.88194.041,131.29115.43
Price / CashN/A57.1640.5538.38
Price / Book1.465.104.724.70
Net Income-$90.21M$151.77M$118.55M$225.32M
7 Day Performance-10.10%-2.45%-2.51%-2.34%
1 Month Performance8.04%-3.71%11.34%2.94%
1 Year Performance-3.82%12.27%30.31%16.90%

Terns Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TERN
Terns Pharmaceuticals
4.1817 of 5 stars
$6.05
+5.0%
$18.30
+202.5%
-6.1%$513.88M$1M-5.1340High Trading Volume
LBPH
Longboard Pharmaceuticals
0.6887 of 5 stars
$59.98
+0.0%
$59.56
-0.7%
+963.5%$2.34BN/A-26.9020
NAMS
NewAmsterdam Pharma
2.8184 of 5 stars
$24.50
-0.8%
$36.20
+47.8%
+137.3%$2.26B$33.59M0.0057Analyst Revision
Gap Down
IDYA
IDEAYA Biosciences
4.2909 of 5 stars
$25.86
+2.7%
$53.67
+107.5%
-28.0%$2.24B$3.92M-10.8180Analyst Forecast
RXRX
Recursion Pharmaceuticals
2.4195 of 5 stars
$7.51
+8.1%
$9.25
+23.2%
-39.3%$2.15B$44.58M-4.85400Gap Up
High Trading Volume
CNTA
Centessa Pharmaceuticals
3 of 5 stars
$16.29
-1.7%
$25.83
+58.6%
+127.9%$2.15B$6.85M-10.8372Insider Trade
APGE
Apogee Therapeutics
2.6219 of 5 stars
$46.76
+5.1%
$83.88
+79.4%
+102.5%$2.11BN/A-18.3991
IBRX
ImmunityBio
2.156 of 5 stars
$3.01
+4.9%
$17.38
+477.2%
-37.3%$2.10B$7.33M-3.36590Gap Up
WVE
Wave Life Sciences
4.889 of 5 stars
$13.57
+1.0%
$22.22
+63.8%
+165.4%$2.07B$113.31M-12.11240Positive News
MIRM
Mirum Pharmaceuticals
4.069 of 5 stars
$42.51
+0.2%
$57.73
+35.8%
+30.3%$2.04B$307.03M-21.01140Positive News
AKRO
Akero Therapeutics
3.9056 of 5 stars
$29.00
+0.4%
$46.83
+61.5%
+23.0%$2.02BN/A-7.7030Insider Trade

Related Companies and Tools


This page (NASDAQ:TERN) was last updated on 12/20/2024 by MarketBeat.com Staff
From Our Partners